A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Aggregation and cytotoxicity of misfolded alpha-synuclein are postulated to be crucial in the disease processes of Parkinson's disease (PD) and other synucleinopathies. Mutations in the alpha-synuclein gene in some pedigrees of familial PD have been reported. The mutant alpha-synuclein has been reported to form fibrillar aggregates resulting in biochemical abnormalities that are responsible for the onset of familial PD. Thus, any agent that effectively prevents the development of misfolded and aggregated alpha-synuclein would be a disease modifying therapeutic candidate. We examined the efficacy of sodium 4-phenylbutyric acid (PBA), one of the chemical chaperons, in transgenic (Tg) mice overexpressing human alpha-synuclein containing a double mutation (A30P + A53T). To evaluate the therapeutic efficacy, bradykinesia and motor coordination were assessed using a pole test and a rotarod treadmill task, respectively. After PBA treatment, these motor deteriorations gradually improved. In immunohistochemical examinations, both a loss of tyrosine hydroxylase-positive neurons and an increase of phosphorylated alpha-synuclein in the substantia nigra were inhibited, resulting in no depletion of the striatal dopamine content. These data suggest that PBA might be one of the therapeutic reagents for neurodegenerative disorders.
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Jonan-ku, Fukuoka, 814-0180, Japan. kazu-ono@fukuoka-u.ac.jp
Kazuhiko
K
Ono
Miyuki
M
Ikemoto
Takeshi
T
Kawarabayashi
Masaki
M
Ikeda
Takuya
T
Nishinakagawa
Masato
M
Hosokawa
Mikio
M
Shoji
Mitsuo
M
Takahashi
Manabu
M
Nakashima
D000818:Animals; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008822:Mice, Transgenic; D018832:Molecular Chaperones / Q000494:pharmacology*; D009154:Mutation; D009410:Nerve Degeneration / Q000517:prevention & control*; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010654:Phenylbutyrates / Q000494:pharmacology*; D051844:alpha-Synuclein / Q000235:genetics*
D018832:Molecular Chaperones; D018696:Neuroprotective Agents; D010654:Phenylbutyrates; D051844:alpha-Synuclein; C075773:4-phenylbutyric acid; D004298:Dopamine